Clinical Trial Detail

NCT ID	NCT03132922
Title	MAGE-A4c1032T for Multi-Tumor
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	no
Sponsors	Adaptimmune
Indications	ovarian cancer cellular myxoid liposarcoma esophageal cancer head and neck squamous cell carcinoma esophagus adenocarcinoma melanoma renal pelvis transitional cell carcinoma ureter transitional cell carcinoma urethra transitional cell carcinoma synovial sarcoma esophagus squamous cell carcinoma lung non-small cell carcinoma bladder urothelial carcinoma stomach cancer
Therapies	Autologous MAGE-A4 C1032 TCR-modified T cells
Age Groups:	adult senior